RQ Biotechnology Ltd: Valuation, Funding & Investors
RQ Biotechnology Ltd (RQ Bio) is a biotechnology company focused on passive immunization, developing potent broad-spectrum monoclonal antibodies (mAbs) to provide immediate and durable protection against viral infections. The company partners with pharmaceutical organizations to discover and advance antibody-based medicines aimed at protecting populations for whom vaccines are ineffective or insufficient, including those at high risk of severe disease from current and future viral threats.
Leadership & Board
Key Executives
- Founder
- Jane Osbourn OBE
- Founder
- Paul Kellam
- Current Number of Employees
- 20
- Current LinkedIn Followers
- 4,552
Latest Estimated Valuation
- Total Amount Raised
- $115M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $115M
- Latest Funding Round
- Series A
Employee Trend
RQ Biotechnology Ltd had 20 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
RQ Biotechnology Ltd had 4,552 followers as of November 16, 2026. The number of followers increased by 174 (3.97%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jul 01, 2026 | Series A | $115.00M | ― |
Similar Companies
A snapshot of private companies similar to RQ Biotechnology Ltd, helping you discover and navigate related company profiles.
Related News and Analysis







